Characteristics | Bolus | Infusion | Total | p-value |
Subjects n | 355 | 347 | 702 | |
Age years | 61.2±15 | 61.9±14 | 61.5±15 | 0.556 |
Males | 207 (58.3) | 197 (56.8) | 404 (57.5) | 0.680 |
Height cm | 170±10.2 | 170±10.4 | 170±10.3 | 0.762 |
Weight kg | 71.5±17.5 | 70.3±17.7 | 70.8±17.6 | 0.350 |
BMI kg·m−2 | 24.7±5.3 | 24.3±5.5 | 24.5±5.4 | 0.340 |
Smoking status % | ||||
Never-smoker | 104 (29.7) | 106 (30.9) | 210 (30.3) | |
Current smoker | 79 (22.6) | 70 (20.4) | 149 (21.5) | 0.782 |
Ex-smoker | 167 (47.7) | 167 (48.7) | 334 (48.2) | |
Pack-years n | 29±30.5 | 27±30 | 28±30.1 | 0.587 |
ASA class % | ||||
I | 7 (2.0) | 4 (1.2) | 11 (1.6) | |
II | 66 (18.6) | 77 (22.2) | 143 (20.4) | 0.514 |
III | 255 (71.8) | 241 (69.5) | 496 (70.7) | |
IV or V | 19 (5.4) | 13 (3.7) | 32 (4.6) | |
Comorbidities % | ||||
COPD | 119 (33.5) | 117 (33.7) | 236 (33.6) | 0.909 |
Coronary artery disease | 52 (14.6) | 45 (13.0) | 97 (13.8) | 0.519 |
Congestive heart failure | 25 (7.0) | 18 (5.2) | 43 (6.1) | 0.310 |
Cerebral vascular disease | 12 (3.4) | 9 (2.6) | 21 (3.0) | 0.541 |
Diabetes mellitus | 47 (13.2) | 37 (10.7) | 84 (12.0) | 0.280 |
Renal failure | 45 (12.7) | 42 (12.1) | 87 (12.4) | 0.807 |
Liver disease | 8 (2.3) | 10 (2.9) | 18 (2.6) | 0.598 |
Solid malignant tumour | 142 (40.0) | 149 (43.0) | 291 (41.5) | 0.429 |
Haematological malignancy | 57 (16.1) | 40 (11.5) | 97 (13.8) | 0.082 |
Immunosuppression | 111 (31.3) | 89 (25.6) | 200 (28.5) | 0.099 |
Rheumatological disease | 22 (6.2) | 17 (4.9) | 39 (5.6) | 0.447 |
HIV | 9 (2.5) | 6 (1.7) | 15 (2.4) | 0.457 |
Alcohol abuse | 27 (7.6) | 22 (6.3) | 49 (7.0) | 0.511 |
Intravenous drug use | 5 (1.4) | 6 (1.7) | 11 (1.6) | 0.736 |
Current medication % | ||||
Acetylsalicylic acid | 68 (19.2) | 56 (16.2) | 124 (17.7) | 0.311 |
Clopidogrel | 8 (2.3) | 11 (3.2) | 19 (2.7) | 0.454 |
Prasugrel | 0 (0) | 2 (0.6) | 2 (0.3) | 0.145 |
Oral anticoagulant | 32 (9.0) | 20 (5.8) | 52 (7.4) | 0.100 |
Heparin (therapeutic dose) | 5 (1.4) | 2 (0.6) | 7 (1.0) | 0.267 |
Heparin (prophylactic dose) | 15 (4.2) | 9 (2.6) | 24 (3.4) | 0.234 |
LMWH (therapeutic dose) | 10 (2.8) | 5 (1.4) | 15 (2.1) | 0.207 |
LMWH (prophylactic dose) | 77 (21.8) | 66 (19.0) | 143 (20.4) | 0.370 |
Sedatives | 29 (8.2) | 21 (6.1) | 50 (7.1) | 0.276 |
Hypnotics | 18 (5.1) | 15 (4.3) | 33 (4.7) | 0.640 |
Mean prothrombin time % | 88.3±23.6 | 90.5±22.0 | 89.4±22.8 | 0.211 |
INR | 1.2±0.7 | 1.2±0.5 | 1.2±0.6 | 0.209 |
Mean platelet count G·L−1 | 318±149 | 338±160 | 329±156 | 0.095 |
Data are presented as mean±sd or n (%), unless otherwise stated. BMI: body mass index; ASA: American Society of Anesthesiologists; COPD: chronic obstructive pulmonary disease; LMWH: low molecular weight heparin; INR: international normalised ratio.